Patents by Inventor Changkon LEE

Changkon LEE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Azaindole derivatives as selective histone deacetylase (HDAC) inhibitors and pharmaceutical compositions comprising the same
    Patent number: 9650379
    Abstract: The present invention relates to novel azaindole derivatives, and more particularly, to novel azaindole derivatives having histone deacetylase (HDAC) inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof or solvates thereof, the use thereof for the preparation of pharmaceutical compositions, pharmaceutical compositions containing the same, a method of treating disease using the pharmaceutical compositions, and methods for preparing the novel azaindole derivatives. The novel azaindole derivatives according to the present invention are selective histone deacetylase (HDAC) inhibitors, and may be used as agents for treating malignant tumor diseases, inflammatory diseases, rheumatoid arthritis, and neurodegenerative diseases.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: May 16, 2017
    Assignee: CHONG KUN DANG PHARMACEUTICAL CORP.
    Inventors: Changsik Lee, Hyun-Mo Yang, Changkon Lee, Miseon Bae, Soyoung Kim, Youngil Choi, Nina Ha, Jaekwang Lee, Jungtaek Oh, Hyeseung Song, Ilhyang Kim, Daekyu Choi, Jaeki Min, Hyojin Lim, Daekwon Bae
  • NOVEL AZAINDOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE (HDAC) INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
    Publication number: 20160289230
    Abstract: The present invention relates to novel azaindole derivatives, and more particularly, to novel azaindole derivatives having histone deacetylase (HDAC) inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof or solvates thereof, the use thereof for the preparation of pharmaceutical compositions, pharmaceutical compositions containing the same, a method of treating disease using the pharmaceutical compositions, and methods for preparing the novel azaindole derivatives. The novel azaindole derivatives according to the present invention are selective histone deacetylase (HDAC) inhibitors, and may be used as agents for treating malignant tumor diseases, inflammatory diseases, rheumatoid arthritis, and neurodegenerative diseases.
    Type: Application
    Filed: December 12, 2014
    Publication date: October 6, 2016
    Applicant: CHONG KUN DANG PHARMACEUTICAL CORP.
    Inventors: Changsik LEE, Hyun-Mo YANG, Changkon LEE, Miseon BAE, Soyoung KIM, Youngil CHOI, Nina HA, Jaekwang LEE, Jungtaek OH, Hyeseung SONG, Ilhyang KIM, Daekyu CHOI, Jaeki MIN, Hyojin LIM, Daekwon BAE